Trestle Holdings, Inc. (OTC BB: TLHO), a
supplier of digital imaging systems for research, clinical and
telepathology applications, announced today that its US patent 6,816,606
"Method for Maintaining High-Quality Focus During High-Throughput,
Microscopic Digital Montage Imaging" with an effective date of November 9,
2005 was available for licensing through its newly created Digital
Pathology Partner Program.

This patent covers the utilization of a slide specific focal map for the
creation of a high quality, in focus scans whole-slide specimen. The
utilization of a focal map with slide specific features provides for high
quality scans achievable in reduced timeframes and at reasonable costs.
This technology further enhances Trestle's product portfolio focused on
bringing integrated digital whole-slide imaging and workflow solutions to
the marketplace.

The Digital Pathology Partner Program provides a partnership for other
providers of digital microscope devices and quantitative and analytical
software to integrate into the Trestle Xcellerator Workflow platform.

"Trestle's intellectual property is applicable to many areas of both live
and digital whole-slide imaging pathology. We are delighted to be able to
license this technology to digital partners. Trestle continues to assemble
a portfolio of important intellectual properties and technologies. These
technologies are designed to facilitate wide spread use of digital
microscopy, as well as to aid end-users by providing the integrated digital
imaging capture and workflow management tools and solutions," said Maurizio
Vecchione, CEO of Trestle Holdings, Inc.

About Trestle Holdings Inc.

Trestle Holdings Inc. develops and sells digital imaging and telemedicine
applications to the both the clinical and life sciences markets. The
Company's products link dispersed users with each other, their information
databases, and analytical tools. This improved integration can drive cost
savings, increase process efficiencies, enable improved pre-clinical and
clinical phases of research and development for new drugs, and enhance
clinical patient care.

Trestle's digital imaging products have the potential to transform the
pathologist work environment by capturing whole-slide digital images of
tissue samples and enabling the sharing, archiving, and analysis of these
images. Its use-case specific digital pathology Workflow and whole-slide
image database management tools complement its image capture products to
provide the pathologist the end-to-end solution in both clinical and
research environments. The Company's live microscopy products allow
multiple physicians and scientists to remotely view, navigate, and share
high fidelity microscope images at sub-micron resolution over standard
Internet connections in real time. The Company's slide scanning and imaging
products perform high-speed whole glass slide digitization for virtual
microscopy applications. Trestle's whole-slide scanning products facilitate
image capture, analysis, workflow and database management, and data mining
and association applications for both clinical and research customers.

Telemedicine enables the remote delivery of patient care using integrated
health information systems and telecommunications technologies. Trestle's
integrated telemedicine products allow scientists, physicians and other
medical professionals around the world to service more patients. Trestle's
telemedicine products use proprietary software and standard computer and
medical hardware to facilitate remote examination, diagnosis, and
treatment.

SAFE HARBOR STATEMENT

This press release contains statements about expected future events that
are forward-looking and subject to risks and uncertainties. For these
statements, we claim the safe harbor for "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Factors that could cause actual results to differ and vary materially from
expectations include, but are not limited to, our efforts to integrate our
recently announce acquisition of the assets of InterScope Technologies, our
ability to expand our product offerings and any transition to new products,
product quality and availability, any change in business conditions,
changes in our sales strategy and product development plans, competitive
pricing pressures, continued market acceptance of our products, name
recognition of our products, delays in the development of new technology,
intellectual property and proprietary rights may not be valid or infringe
the rights of others, changes in customer buying pattern issues, one-time
events and other important factors disclosed previously and from time to
time in our filings with the Securities and Exchange Commission. These
cautionary statements by us should not be construed as exhaustive or as any
admission regarding the adequacy of disclosures made by us. We cannot
always predict or determine after the fact what factors would cause actual
results to differ materially from those indicated by the forward-looking
statements or other statements. In addition, readers are urged to consider
statements that include the terms "believes," "belief," "expects," "plans,"
"objectives," "anticipates," "intends," "targets," "projections," or the
like to be uncertain and forward-looking. All cautionary statements should
be read as being applicable to all forward-looking statements wherever they
appear. We do not undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

CONTACTS:
Investor/PR Contact:
Carol Ruth
+1-646-536-7004
Email Contact
Industry Contact:
Anthony Taddey
1-310-444-4146
Email Contact
SOURCE: Trestle Holdings, Inc.